Document Classification

Section Type: RESULTS

Text: Net adverse clinical events at 30 days occurred in 65 patients (8. 8 %) of 735 who were treated with bivalirudin compared with 96 patients (13. 2 %) of 729 treated with heparin (relative risk [RR], 0. 67 ; 95 % CI, 0. 50-0. 90 ; difference, -4. 3 %, 95 % CI, -7. 5 % to -1. 1 % ; P =. 008) ; and 124 patients (17. 0 %) of 730 treated with heparin plus tirofiban (RR for bivalirudin vs heparin plus tirofiban, 0. 52 ; 95 % CI, 0. 39-0. 69 ; difference, -8. 1 %, 95 % CI, -11. 6 % to -4. 7 % ; P <. 001).